129 related articles for article (PubMed ID: 38134937)
21. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Heczey A; Xu X; Courtney AN; Tian G; Barragan GA; Guo L; Amador CM; Ghatwai N; Rathi P; Wood MS; Li Y; Zhang C; Demberg T; Di Pierro EJ; Sher AC; Zhang H; Mehta B; Thakkar SG; Grilley B; Wang T; Weiss BD; Montalbano A; Subramaniam M; Xu C; Sachar C; Wells DK; Dotti G; Metelitsa LS
Nat Med; 2023 Jun; 29(6):1379-1388. PubMed ID: 37188782
[TBL] [Abstract][Full Text] [Related]
22. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Assessment of CD171-Directed CAR T-cell Adoptive Therapy for Childhood Neuroblastoma: CE7 Epitope Target Safety and Product Manufacturing Feasibility.
Künkele A; Taraseviciute A; Finn LS; Johnson AJ; Berger C; Finney O; Chang CA; Rolczynski LS; Brown C; Mgebroff S; Berger M; Park JR; Jensen MC
Clin Cancer Res; 2017 Jan; 23(2):466-477. PubMed ID: 27390347
[TBL] [Abstract][Full Text] [Related]
24. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
Heczey A; Liu D; Tian G; Courtney AN; Wei J; Marinova E; Gao X; Guo L; Yvon E; Hicks J; Liu H; Dotti G; Metelitsa LS
Blood; 2014 Oct; 124(18):2824-33. PubMed ID: 25049283
[TBL] [Abstract][Full Text] [Related]
25. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
Heczey A; Courtney AN; Montalbano A; Robinson S; Liu K; Li M; Ghatwai N; Dakhova O; Liu B; Raveh-Sadka T; Chauvin-Fleurence CN; Xu X; Ngai H; Di Pierro EJ; Savoldo B; Dotti G; Metelitsa LS
Nat Med; 2020 Nov; 26(11):1686-1690. PubMed ID: 33046868
[TBL] [Abstract][Full Text] [Related]
26. Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours.
Watanabe Y; Tsukahara T; Murata K; Hamada S; Kubo T; Kanaseki T; Hirohashi Y; Emori M; Teramoto A; Nakatsugawa M; Yamashita T; Torigoe T
Br J Cancer; 2023 Mar; 128(5):886-895. PubMed ID: 36526673
[TBL] [Abstract][Full Text] [Related]
27. Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.
Stroncek DF; Lee DW; Ren J; Sabatino M; Highfill S; Khuu H; Shah NN; Kaplan RN; Fry TJ; Mackall CL
J Transl Med; 2017 Mar; 15(1):59. PubMed ID: 28298232
[TBL] [Abstract][Full Text] [Related]
28. An Optimized GD2-Targeting Retroviral Cassette for More Potent and Safer Cellular Therapy of Neuroblastoma and Other Cancers.
Thomas S; Straathof K; Himoudi N; Anderson J; Pule M
PLoS One; 2016; 11(3):e0152196. PubMed ID: 27030986
[TBL] [Abstract][Full Text] [Related]
29. Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells.
Tanaka M; Tashiro H; Omer B; Lapteva N; Ando J; Ngo M; Mehta B; Dotti G; Kinchington PR; Leen AM; Rossig C; Rooney CM
Clin Cancer Res; 2017 Jul; 23(14):3499-3509. PubMed ID: 28183713
[No Abstract] [Full Text] [Related]
30. CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours.
Tang HKC; Wang B; Tan HX; Sarwar MA; Baraka B; Shafiq T; Rao AR
Cells; 2023 Jun; 12(12):. PubMed ID: 37371056
[TBL] [Abstract][Full Text] [Related]
31. Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies.
Zhang J; Webster S; Duffin B; Bernstein MN; Steill J; Swanson S; Forsberg MH; Bolin J; Brown ME; Majumder A; Capitini CM; Stewart R; Thomson JA; Slukvin II
Stem Cell Reports; 2023 Feb; 18(2):585-596. PubMed ID: 36638788
[TBL] [Abstract][Full Text] [Related]
32. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
Del Bufalo F; De Angelis B; Caruana I; Del Baldo G; De Ioris MA; Serra A; Mastronuzzi A; Cefalo MG; Pagliara D; Amicucci M; Li Pira G; Leone G; Bertaina V; Sinibaldi M; Di Cecca S; Guercio M; Abbaszadeh Z; Iaffaldano L; Gunetti M; Iacovelli S; Bugianesi R; Macchia S; Algeri M; Merli P; Galaverna F; Abbas R; Garganese MC; Villani MF; Colafati GS; Bonetti F; Rabusin M; Perruccio K; Folsi V; Quintarelli C; Locatelli F;
N Engl J Med; 2023 Apr; 388(14):1284-1295. PubMed ID: 37018492
[TBL] [Abstract][Full Text] [Related]
33. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.
Li N; Torres MB; Spetz MR; Wang R; Peng L; Tian M; Dower CM; Nguyen R; Sun M; Tai CH; de Val N; Cachau R; Wu X; Hewitt SM; Kaplan RN; Khan J; St Croix B; Thiele CJ; Ho M
Cell Rep Med; 2021 Jun; 2(6):100297. PubMed ID: 34195677
[TBL] [Abstract][Full Text] [Related]
34. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
[TBL] [Abstract][Full Text] [Related]
35. Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.
Singh N; Liu X; Hulitt J; Jiang S; June CH; Grupp SA; Barrett DM; Zhao Y
Cancer Immunol Res; 2014 Nov; 2(11):1059-70. PubMed ID: 25104548
[TBL] [Abstract][Full Text] [Related]
36. Switchable CAR T cell strategy against osteosarcoma.
Hidalgo L; Somovilla-Crespo B; Garcia-Rodriguez P; Morales-Molina A; Rodriguez-Milla MA; Garcia-Castro J
Cancer Immunol Immunother; 2023 Aug; 72(8):2623-2633. PubMed ID: 37062034
[TBL] [Abstract][Full Text] [Related]
37. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo.
Zhang Q; Zhang Z; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Liu G; Tian X; Zhang Z
BMC Cancer; 2022 Nov; 22(1):1124. PubMed ID: 36320072
[TBL] [Abstract][Full Text] [Related]
38. CAR T Cells Offer Hope for Neuroblastoma.
Cancer Discov; 2023 Jun; 13(6):OF2. PubMed ID: 37052406
[TBL] [Abstract][Full Text] [Related]
39. A Reproducible Bioprinted 3D Tumor Model Serves as a Preselection Tool for CAR T Cell Therapy Optimization.
Grunewald L; Lam T; Andersch L; Klaus A; Schwiebert S; Winkler A; Gauert A; Heeren-Hagemann AI; Astrahantseff K; Klironomos F; Thomas A; Deubzer HE; Henssen AG; Eggert A; Schulte JH; Anders K; Kloke L; Künkele A
Front Immunol; 2021; 12():689697. PubMed ID: 34267756
[TBL] [Abstract][Full Text] [Related]
40. CAR T targets and microenvironmental barriers of osteosarcoma.
Zhu J; Simayi N; Wan R; Huang W
Cytotherapy; 2022 Jun; 24(6):567-576. PubMed ID: 35193828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
